MLNT News and Press, Melinta Therapeutics Inc - Ordinary Shares From 02/25/19

Melinta Therapeutics (NASDAQ: MLNT ) announces the closing and receipt of the initial $75M disbursement under the previously announced convertible loan facility from Vatera Healthcare Partners LLC on February 22, 2019. More news on: Melinta Therapeutics, Healthcare stocks news, Stocks on...

– Amendment to Deerfield Facility Agreement Becomes Effective – – John H. Johnson Appointed Permanent Chief Executive Officer – – Company to Report Fourth Quarter and Full Year 2018 Financial Results on March 13, 2019 – MORRISTOWN, N.J....

NEW HAVEN, Conn., Feb. 21, 2019 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ: MLNT), a commercial-stage company focused on the development and commercialization of novel antibiotics to treat serious bacterial infections, today announced that its Board of Directors has approved a o...

Solid Biosciences (NASDAQ: SLDB )  -72%  on disappointing DMD gene therapy data. More news on: Solid Biosciences, Inc., USA Technologies, Inc., Avadel Pharmaceuticals plc, Stocks on the move, Read more ...

Amyris (NASDAQ: AMRS ) +41%  on $255M cannabinoid deal . More news on: Amyris, Inc., Melinta Therapeutics, Moleculin Biotech, Inc., Stocks on the move, Read more ...

Melinta Therapeutics (NASDAQ: MLNT ) provides an update on its strategic repositioning initiatives, cost savings outlook and new appointments. More news on: Melinta Therapeutics, Healthcare stocks news, Read more ...

~ Highlights Continued Positive Sales Momentum and Estimated Year-End Cash Position ~ ~ Confirms Previously Announced Cost Savings Guidance ~   ~ Continues Senior Leadership Team Evolution with New Management Appointments ~ NEW HAVEN, Conn., Feb. 04, 2019 (GLOBE NEWSWIRE) ...

Melinta Therapeutics (NASDAQ: MLNT ) initiated with Buy rating and $15 (249% upside) price target at Jefferies. Shares up  12%  premarket. More news on: Melinta Therapeutics, Tabula Rasa HealthCare, Endo International plc, Healthcare stocks news, Stocks on the move, , Read mo...

NEW HAVEN, Conn., Sept. 06, 2018 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ: MLNT), a commercial-stage company discovering, developing and commercializing novel antibiotics to treat serious bacterial infections, today announced that the company will be attending and hosting meet...